{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:00:16Z","timestamp":1793012416088,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jfma.2022.01.020","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:20:43Z","timestamp":1643847643000},"page":"1929-1937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan"],"prefix":"10.1016","volume":"121","author":[{"given":"Wei-Chun","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5310-3212","authenticated-orcid":false,"given":"Neng-Chuan","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2022.01.020_bib1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"issue":"20 Pt 2","key":"10.1016\/j.jfma.2022.01.020_bib2","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2022.01.020_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib4","first-page":"869","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"DePuy","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jfma.2022.01.020_bib6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"ESMO guidelines committee. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-13-2665","article-title":"Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary","volume":"20","author":"Kluetz","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2022.01.020_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2022.01.020_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.jfma.2022.01.020_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/17512433.2017.1345624","article-title":"Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases","volume":"10","author":"Vogelzang","year":"2017","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.jfma.2022.01.020_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jjco\/hyw038","article-title":"Urologic cancer in Taiwan","volume":"46","author":"Hung","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","article-title":"An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s12253-017-0190-x","article-title":"A retrospective analysis of the first 41 mCRPC patients with bone pain treated with radium-223 at the National Institute of Oncology in Hungary","volume":"23","author":"K\u00fcronya","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jfma.2022.01.020_bib16","first-page":"1467","article-title":"Radium-223 in patients with metastatic castration-resistant prostate cancer: efficacy and safety in clinical practice","volume":"17","author":"Prelaj","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jfma.2022.01.020_bib17","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1038\/s41598-020-63302-2","article-title":"Clinical aspects of mCRPC management in patients treated with radium-223","volume":"10","author":"Rizzini","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jfma.2022.01.020_bib18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/ajco.13479","article-title":"Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: a single-arm phase 3 study","volume":"17","author":"Zhou","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib19","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib20","article-title":"A single-center retrospective analysis of the effect of radium-223 (Xofigo) on pancytopenia in patients with metastatic castration-resistant prostate cancer","volume":"12","author":"Skelton","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jfma.2022.01.020_bib21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pros.23286","article-title":"Clinical correlates of benefit from radium-223 therapy in metastatic castration resistant prostate cancer","volume":"77","author":"Alva","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.jfma.2022.01.020_bib22","doi-asserted-by":"crossref","first-page":"9307","DOI":"10.2147\/CMAR.S213051","article-title":"Population-based analysis of the use of radium-223 for bone-metastatic castration-resistant prostate cancer in Ontario, and of factors associated with treatment completion and outcome","volume":"11","author":"Cheng","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jfma.2022.01.020_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib24","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(16)30173-5","article-title":"Radium-223 International Early Access Program Investigators. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial","volume":"17","author":"Saad","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1634\/theoncologist.2017-0413","article-title":"U.S. Expanded Access Program Investigators. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program","volume":"23","author":"Sartor","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jfma.2022.01.020_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41391-020-00271-7","article-title":"Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center","volume":"24","author":"McKay","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jfma.2022.01.020_bib27","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.clon.2020.05.002","article-title":"Optimising radium 223 therapy for metastatic castration-resistant prostate cancer -5-year real-world outcome: focusing on treatment sequence and quality of Life","volume":"32","author":"Jiang","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MNM.0000000000001325","article-title":"Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway","volume":"42","author":"Jarvis","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.jfma.2022.01.020_bib29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2967\/jnmt.120.254474","article-title":"Review of palliative 223Ra in metastatic castration-resistant prostate cancer: experience at West Virginia University Cancer Center","volume":"49","author":"Arays","year":"2021","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.jfma.2022.01.020_bib30","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2217\/fon-2020-0039","article-title":"Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer","volume":"16","author":"Kuppen","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.jfma.2022.01.020_bib31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10147-020-01776-w","article-title":"Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases","volume":"26","author":"Yamamoto","year":"2021","journal-title":"Int J Clin Oncol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:48:49Z","timestamp":1760539729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0929664622000407"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.01.020","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}